These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 22736392)

  • 1. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
    Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
    Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
    Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
    Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
    Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
    Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M
    Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALDH1 is a prognostic factor for patients treated with neoadjuvant chemoradiotherapy and radical resection for stage III rectal cancer.
    Oh SY; Sohn SH; Yim H; Lee D; Suh KW; Kim YB
    J Surg Oncol; 2015 Feb; 111(2):243-7. PubMed ID: 25270363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients.
    Shinto E; Hashiguchi Y; Ueno H; Kobayashi H; Ishiguro M; Mochizuki H; Yamamoto J; Hase K
    Dis Colon Rectum; 2011 Sep; 54(9):1098-106. PubMed ID: 21825889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.
    Hecht M; Büttner-Herold M; Erlenbach-Wünsch K; Haderlein M; Croner R; Grützmann R; Hartmann A; Fietkau R; Distel LV
    Eur J Cancer; 2016 Sep; 65():52-60. PubMed ID: 27468145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors.
    Lin CH; Chen WT; Liu CH; Tsai HP; Wu CC; Chai CY
    Virchows Arch; 2012 May; 460(5):447-53. PubMed ID: 22453233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy.
    García VM; Batlle JF; Casado E; Burgos E; de Castro J; Belda C; Barriuso J; Sánchez JJ; García-Cabezas MÁ; González-Barón M; Cejas P
    Colorectal Dis; 2011 Sep; 13(9):989-98. PubMed ID: 20718834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Morimoto Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
    Oncol Rep; 2010 Aug; 24(2):345-50. PubMed ID: 20596619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of growth pattern and tumor regression identifies a high-risk group in neoadjuvant treated rectal cancer patients.
    Jessberger J; Erlenbach-Wünsch K; Posselt R; Haderlein M; Agaimy A; Fietkau R; Hartmann A; Distel L
    J Dig Dis; 2017 May; 18(5):283-291. PubMed ID: 28342240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
    Lönnroth C; Andersson M; Nordgren S; Lundholm K
    Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy].
    Cai C; Wang J; Zhong Z; Dai Z; Wang Q; Dong W; Shi H; Liu Q; DU J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):36-43. PubMed ID: 28436629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer.
    Lee HH; Seo KJ; An CH; Kim JS; Jeon HM
    J Surg Oncol; 2012 Dec; 106(8):999-1004. PubMed ID: 22674531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD133 expression in rectal cancer after preoperative chemoradiotherapy.
    Kojima M; Ishii G; Atsumi N; Nishizawa Y; Saito N; Ochiai A
    Cancer Sci; 2010 Apr; 101(4):906-12. PubMed ID: 20219069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
    Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
    Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.